HRP20080117A2 - Pharmaceutical composition for modified release insulin sensitiser - Google Patents

Pharmaceutical composition for modified release insulin sensitiser

Info

Publication number
HRP20080117A2
HRP20080117A2 HR20080117A HRP20080117A HRP20080117A2 HR P20080117 A2 HRP20080117 A2 HR P20080117A2 HR 20080117 A HR20080117 A HR 20080117A HR P20080117 A HRP20080117 A HR P20080117A HR P20080117 A2 HRP20080117 A2 HR P20080117A2
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
modified release
release insulin
insulin sensitiser
insulin sensitizer
Prior art date
Application number
HR20080117A
Other languages
English (en)
Croatian (hr)
Inventor
Glinecke Robert
Marie Milosovich Susan
Muldoon William
Vincenzo Re
Sauer Joseph
Louise Skinner Janet
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824870.1A external-priority patent/GB9824870D0/en
Priority claimed from GBGB9912189.9A external-priority patent/GB9912189D0/en
Application filed by Smithkline Beecham Corporation, Smithkline Beecham P.L.C. filed Critical Smithkline Beecham Corporation
Publication of HRP20080117A2 publication Critical patent/HRP20080117A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20080117A 1998-11-12 1999-11-12 Pharmaceutical composition for modified release insulin sensitiser HRP20080117A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9824870.1A GB9824870D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912189.9A GB9912189D0 (en) 1999-05-25 1999-05-25 Novel composition and use
PCT/EP1999/009031 WO2000028990A1 (fr) 1998-11-12 1999-11-12 Composition pharmaceutique de sensibilisateur modifiant la liberation d'insuline

Publications (1)

Publication Number Publication Date
HRP20080117A2 true HRP20080117A2 (en) 2008-10-31

Family

ID=26314667

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20080117A HRP20080117A2 (en) 1998-11-12 1999-11-12 Pharmaceutical composition for modified release insulin sensitiser
HR20010342A HRP20010342B1 (en) 1998-11-12 1999-11-12 Pharmaceutical composition for modified release insulin sensitiser

Family Applications After (1)

Application Number Title Priority Date Filing Date
HR20010342A HRP20010342B1 (en) 1998-11-12 1999-11-12 Pharmaceutical composition for modified release insulin sensitiser

Country Status (39)

Country Link
EP (3) EP1128827B1 (fr)
JP (1) JP2002529505A (fr)
KR (2) KR100732599B1 (fr)
CN (1) CN1289081C (fr)
AP (2) AP2008004490A0 (fr)
AR (2) AR023700A1 (fr)
AT (1) ATE382352T1 (fr)
AU (1) AU768578B2 (fr)
BG (2) BG109893A (fr)
BR (1) BR9915215A (fr)
CA (1) CA2350659C (fr)
CO (1) CO5190673A1 (fr)
CY (1) CY1107909T1 (fr)
CZ (1) CZ20011628A3 (fr)
DE (1) DE69937898T2 (fr)
DK (1) DK1128827T3 (fr)
DZ (1) DZ2937A1 (fr)
EA (3) EA200601144A1 (fr)
EG (2) EG24463A (fr)
ES (1) ES2299269T3 (fr)
HK (1) HK1040909B (fr)
HR (2) HRP20080117A2 (fr)
HU (1) HUP0104307A3 (fr)
ID (1) ID29344A (fr)
IL (2) IL143003A0 (fr)
MY (1) MY135973A (fr)
NO (1) NO20012351L (fr)
NZ (2) NZ511611A (fr)
OA (1) OA11676A (fr)
PE (1) PE20001428A1 (fr)
PL (1) PL198717B1 (fr)
PT (1) PT1128827E (fr)
RS (1) RS50208B (fr)
SI (1) SI1128827T1 (fr)
SK (1) SK286937B6 (fr)
TR (2) TR200503846T2 (fr)
TW (2) TWI257305B (fr)
UY (2) UY25798A1 (fr)
WO (1) WO2000028990A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
CA2396237A1 (fr) * 2000-01-07 2001-07-19 Jacob Gabriel Michael Activation selective d'une reponse immunitaire regulee par un lymphocyte th1 ou th2
SK287902B6 (sk) * 2001-01-31 2012-03-02 Evonik Rohm Gmbh Multiparticulate drug form and method for the preparation thereof
AU2002367154A1 (en) * 2001-12-21 2003-07-15 Smithkline Beecham Corporation Dosing regimen for ppar-gamma activators
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada
AU2003281181A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
CA2514879C (fr) 2003-01-03 2014-09-16 Shire Laboratories Inc. Utilisation d'un melange de deux ou de plusieurs matieres d'enrobage enteriques afin de reguler la liberation de medicaments
MXPA05007883A (es) 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
FI20060501A7 (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi mahalaukussa
CA2878866C (fr) * 2011-07-14 2021-02-23 Able Cerebral, Llc Composition, dispositif et procede pour la liberation retardee et prolongee de molecules energeniques pour le cerveau
CA2902911C (fr) 2014-10-31 2017-06-27 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1989008650A1 (fr) 1988-03-08 1989-09-21 Pfizer Inc. Agents hypoglycemiques de thiazolidinedione
WO1991007107A1 (fr) 1989-11-13 1991-05-30 Pfizer Inc. Agents d'oxazolidinedione hypoglycemiques
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
KR930701436A (ko) 1990-07-03 1993-06-11 오노다 마사아이 비스헤테로환 화합물
FI930772A0 (fi) 1990-08-23 1993-02-22 Pfizer Hydroxiureaderivat som saenker glugosnivao i blodet
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
CA2106967C (fr) 1991-04-11 2003-12-09 Takashi Sohda Derives thiazolidinedione, leur production et leur utilisation
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (fr) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
WO1993021166A1 (fr) 1992-04-10 1993-10-28 Smithkline Beecham Plc Composes heterocycliques et leur utilisation pour le traitement du diabete du type ii
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
CA2139442A1 (fr) 1992-07-03 1994-01-20 David Haigh Composes heterocycliques pour utilisation en pharmacie
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3256841B2 (ja) * 1996-06-27 2002-02-18 武田薬品工業株式会社 ベンズアルデヒド化合物の製造法
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
BR9808054A (pt) * 1997-03-24 2000-11-07 Galderma Res & Dev Método de tratamento e/ou prevenção de diabete melito não-dependente de insulina e composição

Also Published As

Publication number Publication date
EP1815855A1 (fr) 2007-08-08
AP1901A (en) 2008-10-24
CA2350659A1 (fr) 2000-05-25
CO5190673A1 (es) 2002-08-29
UY25798A1 (es) 2000-12-29
EA200100540A1 (ru) 2001-10-22
DE69937898D1 (de) 2008-02-14
ID29344A (id) 2001-08-23
SK6432001A3 (en) 2001-12-03
HUP0104307A2 (hu) 2002-07-29
BG109893A (bg) 2008-11-28
AU1272900A (en) 2000-06-05
EP1128827A1 (fr) 2001-09-05
EP1917962A1 (fr) 2008-05-07
ATE382352T1 (de) 2008-01-15
CY1107909T1 (el) 2013-09-04
TWI246920B (en) 2006-01-11
EG24463A (en) 2009-07-16
EA200702648A1 (ru) 2008-10-30
KR100732599B1 (ko) 2007-06-27
BR9915215A (pt) 2001-07-31
HRP20010342A2 (en) 2002-06-30
IL183972A0 (en) 2007-10-31
EA007608B1 (ru) 2006-12-29
NO20012351D0 (no) 2001-05-11
NO20012351L (no) 2001-07-04
DE69937898T2 (de) 2009-01-02
NZ511611A (en) 2003-10-31
AU768578B2 (en) 2003-12-18
EA200601144A1 (ru) 2007-02-27
TR200503846T2 (tr) 2007-01-22
CN1289081C (zh) 2006-12-13
EP1128827B1 (fr) 2008-01-02
BG105570A (en) 2002-02-28
KR20060097140A (ko) 2006-09-13
JP2002529505A (ja) 2002-09-10
OA11676A (en) 2005-01-12
ES2299269T3 (es) 2008-05-16
BG65444B1 (bg) 2008-08-29
HK1040909A1 (en) 2002-06-28
KR20010073229A (ko) 2001-07-31
MY135973A (en) 2008-07-31
HUP0104307A3 (en) 2003-12-29
WO2000028990A1 (fr) 2000-05-25
UY25800A1 (es) 2000-08-21
PL198717B1 (pl) 2008-07-31
TW200505436A (en) 2005-02-16
TR200101337T2 (tr) 2001-11-21
PE20001428A1 (es) 2001-02-08
TWI257305B (en) 2006-07-01
CA2350659C (fr) 2009-06-09
AR023700A1 (es) 2002-09-04
DK1128827T3 (da) 2008-04-28
PL348153A1 (en) 2002-05-06
CN1333683A (zh) 2002-01-30
AR023699A1 (es) 2002-09-04
DZ2937A1 (fr) 2004-03-15
RS50208B (sr) 2009-07-15
EG22344A (en) 2002-12-31
NZ526440A (en) 2005-01-28
CZ20011628A3 (cs) 2001-12-12
AP2008004490A0 (en) 2008-06-30
SI1128827T1 (sl) 2008-06-30
SK286937B6 (sk) 2009-07-06
HRP20010342B1 (en) 2008-04-30
IL143003A0 (en) 2002-04-21
PT1128827E (pt) 2008-03-10
YU36401A (sh) 2004-05-12
HK1040909B (en) 2008-08-01

Similar Documents

Publication Publication Date Title
MY124695A (en) Novel composition and use.
HRP20080117A2 (en) Pharmaceutical composition for modified release insulin sensitiser
MEP34008A (en) Novel composition and use
DK1032376T3 (da) Anvendelse af benzhydrylsulfinylderivater til behandling af søvnighed af medicinal oprindelse
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
AR032293A1 (es) Estuche farmaceutico
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
NO330947B1 (no) Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand
UY26139A1 (es) Composiciones de medicamentos a base de compuestos anticolinérgicamente activos y beta- miméticos
HN2000000224A (es) Aminoacidos biciclicos como agentes farmaceuticos
ATE292453T1 (de) Antivirale arznei
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
AU2002223970A1 (en) Kyberdrug as autovaccines with immune-regulating effects
AR012996A1 (es) Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.
GB2429916A (en) Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
ATE314851T1 (de) Synergistische wechselwirkung von abacavir und alovudin
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
ECSP993216A (es) Nueva composicion y uso ii
ATE311883T1 (de) Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
ES2179029T3 (es) Derivados de 14,15-alfa-metileno-equilenina, proceso para su preparacion y medicamentos que contienen los mismos.
UA38697A (uk) Спосіб лікування генералізованого пародонтиту
ECSP993143A (es) Nuevos derivados de benzoilguanidina con ventajosas propiedades, procedimiento para su preparacion y su utilizacion en la preparacion de medicamentos
FR2800276B1 (fr) Composition et medicament, notamment anti-inflammatoire, constitue de ladite composition
ECSP993215A (es) Nueva composicion y uso

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20091026

Year of fee payment: 11

OBST Application withdrawn